Abstract:Glycogen synthase kinase-3 (GSK3) is one of the important serine/threonine protein kinases and has two isoforms, namely, GSK3α and GSK3β. GSK3 inhibits glycogen synthase activity through phosphorylation. It plays a key role in various pathophysiological processes, such as differentiation, immunity, metabolism, cell death, and cell survival. Therefore, GSK3 has evolved as an important therapeutic target for treating neurological diseases, inflammatory diseases, and cancer. In addition, GSK3 regulates inflammatory processes through NF-κB-induced expression of various cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6. Moreover, GSK3 is reported to participate in many signaling pathways related to disease pathology, including PI3K/Akt, Wnt, Hedgehog, cyclic adenosine monophosphate, mitogen-activated protein kinase, and transforming growth factor-β (TGF-β). GSK3 has become a therapeutic target against some inflammatory diseases, including the inclusion body myositis, sepsis, and inflammatory bowel disease. Hence, several GSK3 inhibitors have been under evaluation as new therapeutic strategies in recent years. Two drugs targeting GSK3 have already entered clinical studies, including tideglusib and lithium carbonate. In this study, we analyzed nearly 30 different small-molecule GSK3 inhibitors reported in the past 4 years and classified them into four categories (thiazole, pyridine, F-substituted benzene, and others) according to their structure to conduct further literature research. Moreover, we summarized the optimal compounds and described the process of transformation from the lead compound to the optimal compound. In addition, we aimed to summarize the role of GSK3 in the pathogenesis of inflammatory diseases, with insights into the recent progress in the discovery of GSK3 inhibitors.

Advances in Study of Glycogen Synthase Kinase-3β and Its Inhibitors

Studies of glycogen synthase kinase-3 inhibitors

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Development of Inhibitors Targeting Glycogen Synthase Kinase-3Β for Human Diseases: Strategies to Improve Selectivity.

Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases

Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

Biological Evaluation and Energetic Analyses of Novel GSK‐3β Inhibitors

Association of Glycogen Synthase Kinase-3Β with Parkinson’s Disease (Review)

Design, Synthesis, and Evaluation of 3‐aryl‐4‐pyrrolyl‐maleimides As Glycogen Synthase Kinase‐3β Inhibitors

Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease

Targeting Glycogen Synthase Kinase-3Β for Alzheimer's Disease: Recent Advances and Future Prospects

Glycogen Synthase Kinase 3 Beta In Tumorigenesis And Oncotherapy

GSK-3 in Neurodegenerative Diseases

The Key Roles of GSK-3β in Regulating Mitochondrial Activity

Glycogen synthase kinase-3: A potential target for diabetes

Glycogen synthase kinase-3 (GSK3): Regulation, actions and diseases.

The Role of Glycogen Synthase Kinase 3 Beta in Neurodegenerative Diseases

Glycogen synthase kinase 3 and neurophysiology

GSK3: A potential target and pending issues for treatment of Alzheimer's disease